TY - JOUR AU - Szeitz, Beáta AU - Pipek, Orsolya Anna AU - Kulka, Janina AU - Szundi, Csilla AU - Rusz, Orsolya AU - Tőkés, Tímea AU - Szász, Attila Marcell AU - Kovács, Attila AU - Pesti, Adrián István AU - Ben Arie, Taya Beri AU - Gángó, Ambrus AU - Fülöp, Zsolt AU - Drágus, Emőke AU - Vári-Kakas, Stefan A. AU - Tőkés, Anna-Mária TI - Investigating the Prognostic Relevance of Tumor Immune Microenvironment and Immune Gene Assembly in Breast Carcinoma Subtypes JF - CANCERS J2 - CANCERS VL - 14 PY - 2022 IS - 8 PG - 22 SN - 2072-6694 DO - 10.3390/cancers14081942 UR - https://m2.mtmt.hu/api/publication/32793328 ID - 32793328 LA - English DB - MTMT ER - TY - JOUR AU - Kajary, Kornelia AU - Lengyel, Zsolt AU - Tőkés, Anna-Mária AU - Kulka, Janina AU - Dank, Magdolna AU - Tőkés, Tímea TI - Response Evaluation with Dynamic FDG PET/CT during the Primary Systemic Therapy of Breast Cancer - A Case Report JF - ANNALS OF CLINICAL ONCOLOGY J2 - ACO VL - 4 PY - 2021 IS - 1 SP - 1 EP - 4 PG - 4 SN - 2674-3248 DO - 10.31487/j.ACO.2021.01.02 UR - https://m2.mtmt.hu/api/publication/33137925 ID - 33137925 AB - 18-fluorine-fluorodeoxyglucose (FDG) positron emission tomography (PET) and mainly combined with computed tomography (CT), abbreviated as FDG PET/CT is a useful and accurate tool for staging and restaging in locally advanced breast cancer. In daily practice static images are prepared during the PET/CT examinations. However, despite the success of static PET and PET/CT imaging, the role of precise quantification of FDG-uptake – measured by dynamic acquisition – is ambiguous in the staging and management of different malignancies. In this case report, we described our experience with staging, interim and restaging dynamic PET/CT examinations of a woman suffering from breast cancer. Based on the described case we concluded that dynamic PET/CT is suitable for accurate quantification of FDG-uptake in primary breast tumors. However, performing dynamic PET/CT examinations is time-consuming, therefore, it is important to define the group of patients where their use is with the most favourable benefit/risk ratio. Furthermore, using of interim PET/CT scan is recommended in cases with clinically controversial baseline tests. Based on literature in vivo biomarkers of the dynamic PET/CT are predictive of more favourable tumor response and longer disease-free survival, as confirmed by our own results. LA - English DB - MTMT ER - TY - JOUR AU - Tőkés, Tímea AU - Tőkés, Anna-Mária AU - Szentmártoni, Gyöngyvér AU - Kiszner, Gergő AU - Mühl, Dorottya AU - Molnár, Béla Ákos AU - Kulka, Janina AU - Krenács, Tibor AU - Dank, Magdolna TI - Prognostic and Clinicopathological Correlations of Cell Cycle Marker Expressions before and after the Primary Systemic Therapy of Breast Cancer. JF - PATHOLOGY AND ONCOLOGY RESEARCH J2 - PATHOL ONCOL RES VL - 26 PY - 2020 IS - 3 SP - 1499 EP - 1510 PG - 12 SN - 1219-4956 DO - 10.1007/s12253-019-00726-w UR - https://m2.mtmt.hu/api/publication/30785775 ID - 30785775 N1 - Oncology Center, Semmelweis University, Tömő utca 25-29, 4th floor, Budapest, H-1083, Hungary 2nd Department of Pathology, Semmelweis University, Üllői út 93, Budapest, H-1091, Hungary 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, Budapest, H-1085, Hungary 1st Department of Surgery, Semmelweis University, Üllői út 78/A, Budapest, H-1083, Hungary Export Date: 12 May 2021 CODEN: POREF Correspondence Address: Tőkés, T.; Oncology Center, Tömő utca 25-29, 4th floor, Hungary; email: timi.tokes@gmail.com Funding Agency and Grant Number: Hungarian Cancer Society [student scholarship] Funding Source: Medline; Semmelweis University Doctoral School [student scholarship and PhD budget] Funding Source: Medline; Semmelweis Scientific and Innovation Fund [STIA 19/2017, 6800313113, 68003F0043 scholarships] Funding Source: Medline; New National Excellence Program [UNKP-17-4-III-SE-71] Funding Source: Medline Oncology Center, Semmelweis University, Tömő utca 25-29, 4th floor, Budapest, H-1083, Hungary 2nd Department of Pathology, Semmelweis University, Üllői út 93, Budapest, H-1091, Hungary 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, Budapest, H-1085, Hungary 1st Department of Surgery, Semmelweis University, Üllői út 78/A, Budapest, H-1083, Hungary Export Date: 16 May 2021 CODEN: POREF Correspondence Address: Tőkés, T.; Oncology Center, Tömő utca 25-29, 4th floor, Hungary; email: timi.tokes@gmail.com AB - We aimed to analyze the expression of cell-cycle regulation markers - minichromosome maintenance protein 2 (MCM2), Ki-67, Cyclin-A and phosphohistone-H3 (PHH3) - in pre-treatment core-biopsy samples of breast carcinomas in correlation with known predictive and prognostic factors. Totally 52 core biopsy samples obtained prior to neoadjuvant therapy were analyzed. Immunohistochemistry was performed to analyze the expression of MCM2, Ki-67, Cyclin A and PHH3, which were correlated with the following clinicopathological parameters: clinical TNM, tumor grade, biological subtype, the presence of tumor infiltrating lymphocytes (TIL), pathological tumor response rate to the neoadjuvant therapy and patient survival. All investigated markers showed higher expression in high grade and in triple negative tumors (p < 0.01 and p < 0.05, respectively). Hormone receptor negative tumors showed significantly higher expression of Ki-67 (p < 0.01), MCM2 (p < 0.01) and Cyclin A (p < 0.01) than hormone receptor positive ones. Tumors with increased TIL showed significantly higher Ki-67 expression (p = 0.04). Pattern analysis suggested that novel cell-cycle marker-based subgrouping reveals predictive and prognostic potential. Tumors with high MCM2, Cyclin A or PHH3 expression showed significantly higher rate of pathological complete remission. Tumors with early relapse (progression-free survival ≤2 years) and shortened overall survival also show a higher rate of proliferation. Our cell cycle marker (Ki-67, MCM2, Cyclin A, PHH3) based testing could identify tumors with worse prognosis, but with a favorable response to primary systemic therapy. The pattern of cell-cycle activity could also be useful for predicting early relapse, but our findings need to be further substantiated in larger patient cohorts. LA - English DB - MTMT ER - TY - JOUR AU - Kajáry, Kornélia AU - Lengyel, Zsolt AU - Tőkés, Anna-Mária AU - Kulka, Janina AU - Dank, Magdolna AU - Tőkés, Tímea TI - Dynamic FDG-PET/CT in the Initial Staging of Primary Breast Cancer. Clinicopathological Correlations TS - Clinicopathological Correlations JF - PATHOLOGY AND ONCOLOGY RESEARCH J2 - PATHOL ONCOL RES VL - 26 PY - 2020 IS - 2 SP - 997 EP - 1006 PG - 10 SN - 1219-4956 DO - 10.1007/s12253-019-00641-0 UR - https://m2.mtmt.hu/api/publication/30639011 ID - 30639011 AB - Our aim was to evaluate correlation between clinicopathological features (clinical T and clinical N stages; histological type; nuclear grade; hormone-receptor and HER2 status, proliferation activity and tumor subtypes) of breast cancer and kinetic parameters measured by staging dynamic FDG-PET/CT examinations. Following ethical approval and patients' informed consent we included 34 patients with 35 primary breast cancers in our prospective study. We performed dynamic PET imaging, and assessed plasma activity noninvasively. To delineate primary tumors we applied a frame-by-frame semi-automatic software-based correction of motion artefacts. FDG two-compartment kinetic modelling was applied to assess K1, k2, k3 rate coefficients and to calculate Ki (tracer flux constant) and MRFDG (FDG metabolic rate). We found that k3, Ki and MRFDG were significantly higher in higher grade (p = 0.0246, 0.0089 and 0.0076, respectively), progesterone-receptor negative (p = 0.0344, 0.0217 and 0.0132) and highly-proliferating (p = 0.0414, 0.0193 and 0.0271) tumors as well as in triple-negative and hormone-receptor negative/HER2-positive subtypes (p = 0.0310, 0.0280 and 0.0186). Ki and MRFDG were significantly higher in estrogen-receptor negative tumors (p = 0.0300 and 0.0247, respectively). Ki was significantly higher in node-positive than in node-negative disease (p = 0.0315). None of the assessed FDG-kinetic parameters showed significant correlation with stromal TIL. In conclusion, we confirmed a significant relationship between kinetic parameters measured by dynamic PET and the routinely assessed clinicopathological factors of breast cancer: high-grade, hormone-receptor negative tumors with high proliferation rate are characterized by higher cellular FDG-uptake and FDG-phosphorylation rate. Furthermore, we found that kinetic parameters based on the dynamic examinations are probably not influenced by stromal TIL infiltration. LA - English DB - MTMT ER - TY - JOUR AU - Tőkés, Tímea AU - Dank, Magdolna AU - Lengyel, Zsolt AU - Kajáry, Kornélia TI - Comparison of different motion correction techniques for dynamic FDG-PET/CT studies in breast cancer patients. JF - QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING J2 - Q J NUCL MED MOL IM VL - 64 PY - 2020 IS - 4 SP - 406 EP - 413 PG - 8 SN - 1824-4785 DO - 10.23736/S1824-4785.19.03114-5 UR - https://m2.mtmt.hu/api/publication/30639008 ID - 30639008 AB - Our aim was evaluate interchangeability of different motion correction methods in the assessment of dynamic FDG-PET/CT studies in breast cancer patients as well as to assess the interrater reliability of these methods.In our prospective study we included patients with malignant breast tumours. Dynamic PET acquisition lasted for 60 minutes after tracer (FDG) injection. Every study was assessed by the same two experienced observers. We assessed plasma activity noninvasively. In case of the primary tumour VOIs we applied two different approaches to correct motion artefacts: Method I) frame-by-frame manual motion correction; Method II) frame-by-frame semi-automatic software-based motion correction. FDG two-compartment kinetic modelling was applied to assess K1, k2, k3 rate coefficients and to calculate Ki (tracer flux constant) and MRFDG (FDG metabolic rate).35 lesions detected during 34 dynamic studies were included in this current analysis. Interrater reliability of both applied motion correction methods proved to be excellent (ICC= 0.89-0.99), except Ki measured by Method I (ICC=0.66). Bland-Altman analysis revealed that Method II resulted in significantly lower values than Method I regarding k3 and Ki in case of both observers, and regarding MRFDG in one of the observers. In case of K1 and k2 the two methods were in good agreement.Both applied methods proved to be reproducible and reliable, especially Method II, where every measured kinetic parameter showed excellent interrater reliability. Different approaches of motion correction could have a significant effect on the results of the kinetic modelling; therefore careful selection of the most reliable method is advised. LA - English DB - MTMT ER - TY - JOUR AU - Török, Judit AU - Czibor, Sándor AU - Tőkés, Tímea AU - Györke, Tamás TI - 18F-FDG-PET/CT SZEREPE A PRIMER SZISZTÉMÁS TERÁPIÁBAN RÉSZESÜLŐ EMLŐDAGANATOS BETEGEK TERÁPIÁS VÁLASZÁNAK MEGHATÁROZÁSÁBAN JF - MAGYAR RADIOLÓGIA ONLINE J2 - MAGYAR RADIOLÓGIA ONLINE VL - 10 PY - 2019 IS - 2019/3 SP - 46 SN - 2063-9481 UR - https://m2.mtmt.hu/api/publication/30939173 ID - 30939173 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Török, Judit AU - Czibor, Sándor AU - Tőkés, Tímea AU - Györke, Tamás TI - The role of 18F-FDG-PET/CT in the response evaluation of primary systemic therapy in breast cancer JF - EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING J2 - EUR J NUCL MED MOL I VL - 46 PY - 2019 IS - Suppl. 1. SP - S525 SN - 1619-7070 UR - https://m2.mtmt.hu/api/publication/30855177 ID - 30855177 LA - English DB - MTMT ER - TY - BOOK ED - Désfalvi, Judit ED - Újháziné, Kerék Barbara AU - Bálintné, Pataki Aranka AU - Brjeska, Dóra AU - Dank, Magdolna AU - Dvorákné, Borda Judit AU - Hajdú, Anett AU - Horváth, Katalin Beatrix AU - Juhász, Ágnes AU - Kleiner, Dénes AU - Kovács, Eszter AU - Németh, Zsuzsanna AU - Petrányi, Ágota Eszter AU - Tőkés, Tímea TI - Gyógyulásom Könyve PB - Pink Bolero Önsegítő Egyesület a Mellrák Ellen CY - Budapest PY - 2019 SN - 9786150042954 UR - https://m2.mtmt.hu/api/publication/30709143 ID - 30709143 AB - https://gyogyulasomkonyve.hu/ Régi verzió: https://www.gyogyulaskonyvem.hu/mobilbarat/ https://www.gyogyulasomkonyve.hu/teljes_kiadvany/ LA - Hungarian DB - MTMT ER - TY - JOUR AU - Tőkés, Anna-Mária AU - Rusz, Orsolya AU - Cserni, Gábor AU - Tóth, Erika AU - Rubovszky, Gábor AU - Tőkés, Tímea AU - Vízkeleti, Laura AU - Reiniger, Lilla AU - Kószó, Renáta Lilla AU - Kahán, Zsuzsanna AU - Kulka, Janina AU - Donia, Marco AU - Vörös, András AU - Szállási, Zoltán TI - Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune infiltration of residual breast cancer JF - ACTA ONCOLOGICA J2 - ACTA ONCOL VL - 58 PY - 2019 IS - 11 SP - 1603 EP - 1611 PG - 9 SN - 0284-186X DO - 10.1080/0284186X.2019.1633015 UR - https://m2.mtmt.hu/api/publication/30658783 ID - 30658783 N1 - Funding Agency and Grant Number: New National Excellence Program [UNKP-17-4-II-SE-65, UNKP-17-4-III-SE-71]; STIA [19/2017, 6800313113, 68003F0043]; Research and Technology Innovation Fund [KTIA_NAP_13-2014-0021]; Breast Cancer Research Foundation; [NVKP_16-1-2016-0004]; [NKP-2017-00002] Funding text: This work is supported by New National Excellence Program [UNKP-17-4-II-SE-65] (L.V); New National Excellence Program [UNKP-17-4-III-SE-71] (AMT); NVKP_16-1-2016-0004; STIA 19/2017, 6800313113, 68003F0043 (AMT); The Research and Technology Innovation Fund [KTIA_NAP_13-2014-0021 to Z.S.]; NKP-2017-00002 (Z.S.); Breast Cancer Research Foundation (Z.S.). LA - English DB - MTMT ER - TY - JOUR AU - Ács, Balázs AU - Zambo, V AU - Vízkeleti, Laura AU - Szász, Attila Marcell AU - Madaras, Lilla AU - Szentmártoni, Gyöngyvér AU - Tőkés, Tímea AU - Molnár, Béla Ákos AU - Molnár, István Artúr AU - Vari-Kakas, S AU - Kulka, Janina AU - Tőkés, Anna-Mária TI - Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy. JF - DIAGNOSTIC PATHOLOGY J2 - DIAGN PATHOL VL - 12 PY - 2017 IS - 1 PG - 12 SN - 1746-1596 DO - 10.1186/s13000-017-0608-5 UR - https://m2.mtmt.hu/api/publication/3200423 ID - 3200423 N1 - Megosztott első szerzőség AB - BACKGROUND: Studies have partly demonstrated the clinical validity of Ki-67 as a predictive marker in the neoadjuvant setting, but the question of the best cut-off points as well as the importance of this marker as a prognostic factor in partial responder/non-responder groups remains uncertain. METHODS: One hundred twenty patients diagnosed with invasive breast cancer and treated with neoadjuvant chemotherapy (NAC) between 2002 and 2013 were retrospectively recruited to this study. The optimal cut-off value for Ki-67 labeling index (LI) to discriminate response to treatment was assessed by receiver operating characteristic (ROC) curve analysis. Kaplan-Meier curve estimation, log-rank test and cox regression analysis were carried out to reveal the association between Ki-67 categories and survival (DMFS = Distant metastases-free survival, OS = Overall survival). RESULTS: Twenty three out of 120 patients (19.2%) achieved pathologic complete remission (pCR), whereas partial remission (pPR) and no response (pNR) to neoadjuvant chemotherapy (NAC) was detected in 60.8% and 20.0%, respectively. The distribution of subtypes showed a significant difference in pathological response groups (p < 0.001). Most of the TNBC cases were represented in pCR group. The most relevant cut-off value for the Ki-67 distinguishing pCR from pNR cases was 20% (p = 0.002). No significant threshold for Ki-67 was found regarding DMFS (p = 0.208). Considering OS, the optimal cut-off point occurred at 15% Ki-67 (p = 0.006). The pPR group represented a significant Ki-67 threshold at 30% regarding OS (p = 0.001). Ki-67 and pPR subgroups were not significantly associated (p = 0.653). For prognosis prediction, Ki-67 at 30% cut-off value (p = 0.040) furthermore subtype (p = 0.037) as well as pathological response (p = 0.044) were suitable to separate patients into good and unfavorable prognosis cohorts regarding OS. However, in multivariate analyses, only Ki-67 at 30% threshold (p = 0.029), and subtype (p = 0.008) were independently linked to OS. CONCLUSIONS: NAC is more efficient in tumors with at least 20% Ki-67 LI. Both Ki-67 LI and subtype showed a significant association with pathological response. Ki-67 LI represented independent prognostic potential to OS in our neoadjuvant patient cohort, while pathological response did not. Additionally, our data also suggest that if a tumor is non-responder to NAC, increased Ki-67 is a poor prognostic marker. LA - English DB - MTMT ER -